|
|
|
|
LEADER |
00000cam a2200000Mu 4500 |
001 |
EBOOKCENTRAL_ocn779141406 |
003 |
OCoLC |
005 |
20240329122006.0 |
006 |
m o d |
007 |
cr |n|---||||| |
008 |
120305s2011 xx o 000 0 eng d |
040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d BENTH
|d OCLCQ
|d YDXCP
|d OCLCQ
|d ZCU
|d MERUC
|d U3W
|d OCLCO
|d OCLCF
|d OCLCQ
|d OCLCO
|d STF
|d ICG
|d OCLCQ
|d WYU
|d TKN
|d DKC
|d AU@
|d OCLCQ
|d HS0
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|
020 |
|
|
|a 9781608051625
|
020 |
|
|
|a 1608051625
|
029 |
1 |
|
|a DEBBG
|b BV044162586
|
035 |
|
|
|a (OCoLC)779141406
|
050 |
|
4 |
|a RS431.A64
|
082 |
0 |
4 |
|a 600
|
049 |
|
|
|a UAMI
|
100 |
1 |
|
|a Atta-ur-Rahman.
|
245 |
1 |
0 |
|a Anti-Angiogenesis Drug Discovery and Development.
|
260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2011.
|
300 |
|
|
|a 1 online resource (197 pages)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
520 |
|
|
|a The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery scien.
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a Preface; Contributors; Antiangiogenic Treatment of Hematological Tumors; Multiligands/Rage Axis: An Emerging Actor in Tumour Angiogenesis; Ginsenoside Rg3 and Rh2: The Anti-Cancer and Anti-Angiogenic Saponins from Ginseng; Antiangiogenic Therapy for Cardiovascular Diseases; Role of Phosphoinositide 3-Kinases and Angiogenesis in Cardiovascular Diseases; Redox Regulation of Angiogenesis: NADPH Oxidase as a Drug Target; Thymidine Phosphorylase Inhibitors; Neurological Complications of Antiangiogenic Therapy; Autoimmunity and Angiogenesis; Author Index
|
590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
650 |
|
0 |
|a Drug development.
|
650 |
|
0 |
|a Neovascularization inhibitors.
|
650 |
|
0 |
|a Neovascularization.
|
650 |
|
2 |
|a Angiogenesis Inhibitors
|
650 |
|
2 |
|a Neovascularization, Pathologic
|
650 |
|
6 |
|a Médicaments
|x Développement.
|
650 |
|
6 |
|a Néovascularisation
|x Inhibiteurs.
|
650 |
|
6 |
|a Néovascularisation.
|
650 |
|
7 |
|a Drug development
|2 fast
|
650 |
|
7 |
|a Neovascularization
|2 fast
|
650 |
|
7 |
|a Neovascularization inhibitors
|2 fast
|
700 |
1 |
|
|a Choudhary, M. Iqbal.
|
776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rahman.
|t Anti-Angiogenesis Drug Discovery and Development.
|d Sharjah : Bentham Science Publishers, ©2011
|
856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=864219
|z Texto completo
|
938 |
|
|
|a Bentham Science Publisher
|b BENT
|n 9781608051625
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL864219
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 7209694
|
994 |
|
|
|a 92
|b IZTAP
|